A review of new drugs for treatment of IBD

Perhaps you’re getting confused by all the medications that are now available for treating IBD. A recent article in IBD discusses the drugs by groups.

Year ago all we had to treat IBD was prednisone. Sulfasalazine ushered in the era of mesalamine drugs. Azathioprine was available as well. Then it got interesting. Our colleagues in immunology research looked into what drove the immune response and identified cachexin, also known as Tumor Necrosis Factor alpha, or TNF-α for short, as a major signaling protein in immune responses. cA2 was an antibody directed against TNF-α, which was shown to be useful in Crohn’s. Soon named Infliximab, the antibody revolutionized treatment of inflammatory bowel disease.

But our immunology colleagues have not been idle. The immune response control system has ben studied for years now, and additional targets ahve been identified in the immune system. We now have more drugs than we could have dreamed of years ago for the treatment of IBD.

A recent review [1] published in IBD Inflammatory Bowel Diseases, a journal of the Crohn’s nd Colitis foundation has provided a nice summary of some current and new drugs for use in IBD. It’s worth a read. I’m providing some highlights here.

First off, the graphic on the cover of IBD is awesome. The immune system is complex, and a cartoon such as was on the cover is very helpful in putting a model in the readers head. I took this diagram off the cover of the issue of IBD. I really like the diagram. You can see that it shows a number of the molecules that are involved in the immune system of IBD.

Anti-adhesion agents

First mentioned in the review are the Anti-adhesion agents. You see, for the immune system to deliver immune cells to that are of inflammation, the cells of the immune system have to migrate to the area on inflammation. I recall stunning videos of immune cells whipping around in the vascular system, with cells stiopping in surreal instantaneity at the place they need to migrate, and then migrate through the wall of the blood vessel to the are of inflammation. If you can stop cells from finding where they need to go, the immune cells will not get to their targets and an inflammatory resposnse can be prevented. Natalizumab was the first drug in category to come to clinical practice. A protein on the surface of immune cels, α4β7/α4β1, binds to a structure named MAdCAM-1 and a structure on the inner surface of blood vessels (VCAM-1 – Vascular Cell Adhesion Molecule-1). Natalizumab is an antobody that binds to α4β7/α4β1, shich bloks cells from binding to blood vessel linings, thus preventing an immune response.

Regretably, natalizumab has been associated with the develoopment of Progressive Multifocal Leucoencephalopathy, a dangerouse disease caused by reactivation of infection by the JC virus, a not uncommon infection that the immune system usually keeps under control.

This is an example of how, even though we have a promising new drug, surprises appear when we block the immune system, allowing an infection that stays controlled by the immune system.

Vedolizumab is another anti adhesion drug. This antobody just blocks the α4β7 protein. Progressive Multifocal Leucoencephalopathy does not seem to occur with this drug. The review nicely describes the studies that support the use of Vedolizumab.

The review describes a drug under study, Etrolizumab, which is directed against the β7 molecule, so it is effective in interfering with several of the proteins that are involved with cell binding to surfaces.

AJM300 is another drug under study, but is special because it is not an antibody. It is a small molecule which blocks immune cell binding to the MAdCAM-1 and VCAM-1 proteins. This is a welcome new agent, as it can be taken as a pill rather than an injection, which is needed by antibodies. Time will tell what adverse reactions happen. Certainly, the incidence of progressive multifocal leucoencephalopathy will need to be watched for, since that problem was seen with natalizumab.

Anti-interleukin Inhibitors

Aside from TNF-α, other immune proteins are involved in the cascade of immune reactions that drive inflammatory bowel disease. IL-2, IL-12, IL-23 are all important. While prednisone blocks IL-2, the drug ustekinumab blocks IL12 and IL-20. It is effective in Crohn’s disease and psoriasis.

Risankizubmab is under development. It looks like it will also be effective in Crohn’s disease.

JAK/STAT inhibitors

In the immune system a number of chemicals are important in regulation of the immune system besides the interleukins. That is because the proteins that regulate the immune system interact with cells which then elaborate internal chemicals in response to stimulation by the interleukins. One such system is the JAK/STAT proteins. If those cellular signalling systems can be blocked then the immune system can be shut down in another way.

Tofacitinib is currently on the market, and works by blocking the JAK system. It works in Psoriasis and Ulcerative Colitis. It is a small molecule, and taken as a pill rather than an injection.

Filgotinib also blocks the JAK system, but works better in Crohn’s disease. It is currently under investigation.

Spingosine-1-phosphate receptor modulators

The review gives short shrift to this class of immun modulators, and honestly, I need to brush up on this system to tell more about what it does in the body. A drug, Ozamimodh is a small moledule orally administered It is in development and is promising for Ulcerative Colitis.

Stem Cell Therapy for perianal Crohn’s Disease

The review describes the injection of stem cells for treatment of perianal fistulas. As the review states, it isn’t known how stem cells work. These are very experimental treatments. The therapy advertised which uses cells from the stems of plants are not stem cells in the sense of stem cells from humans and have nothing to do with this.

Conclusion

This review looks over the new therapies of Anti-adhesion agents, Anti-interleukin Inhibitors, JAK/STAT inhibitors, Spingosine-1-phosphate receptor modulators, and Stem Cell Therapy. While it is written fo rthe professional, a non-professional can glean the complexity of the immune system and the exciting new options for treatment that the future protends. I’d quibble with the term Anti-interleukin Inhibitors since Anti-interleukin antibodies would be a better term. But overall the paper does describe new treatments that are available and others that will be available in the future.

Reference:

1 – A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Chudy-Onwugaje KO, Christian KE, Farraye FA, Cross RK. Inflamm Bowel Dis. 2019 Apr 11;25(5):820-830.

Author: Stephen Holland

Stephen Holland, M.D. went to medical school at Northwestern University in Chicago, then did his medical residency at Loyola in Maywood (just West of Chicago). He then did research at the University of Alabama at Birmingham, did his GI fellowship there, and went to the University of Illinois at Peoria to teach and do research. He ran a successful private practice for over 12 years in Naperville, Illinois. Most recently he is an Assistant Professor of Medicine at SIU School of Medicine and is in practice in Decatur, IL